PDS Biotech drops PDS0101 Phase 3 trial, shifts focus to PDS0301 in colorectal cancer

PDS Biotechnology announced on August 11, 2026 a strategic realignment of its pipeline, disclosed in an 8-K shareholder letter from CEO Frank Bedu-Addo. The company said its board and management reviewed the development portfolio and capital allocation and concluded that the best route to long-term shareholder value is to prioritize advancing PDS0301, its tumor-targeted immunocytokine, while seeking strategic partnerships for PDS0101.¹

The company reported that it will stop internal investment in the PDS0101 Phase 3 VERSATILE-003 trial, discontinuing that study, and will instead pursue partnerships or other externally funded paths for PDS0101's development.¹ PDS Biotech said this followed a review of the capital, time and resources needed to finish the Phase 3 trial and bring PDS0101 to market.¹ The company added that the decision does not reflect a change in its view of PDS0101's underlying science or clinical data, but rather reflects a disciplined capital allocation approach.¹

For PDS0301, the company cited Phase 2 data in metastatic microsatellite-stable, mismatch repair-proficient colorectal cancer with liver metastases, generated with the National Cancer Institute, showing a 71% objective response rate at 6 months and an 80% 24-month survival rate¹, with safety data from more than 380 treated patients.¹

Looking forward, PDS Biotech said a randomized Phase 2b trial for PDS0301 has been designed incorporating FDA feedback and aims to produce clinically meaningful data while keeping capital spending controlled.¹ Over the coming year and a half to two years, the company said it plans to move PDS0301 through this Phase 2b program, pursue partnering deals for PDS0101, and keep capital allocation disciplined while hitting clinical and business milestones.¹ PDS Biotech also confirmed it will report second-quarter 2026 financial results on August 13, 2026.